Polycythemia - 55 Studies Found
Not yet recruiting |
: Incidence of Iron Deficiency in Polycythemia Vera (PV) and Association With Disease Features : Polycythemia Vera : 2016-06-18 : Other: questionnaires • Influence of iron parameters on Patient-reported symptoms as assessed by M |
Recruiting |
: A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera : Polycythemia Vera : 2013-07-10 : Drug: Givinostat In Part A patients will treated in dose l |
Completed |
: Treatment of Polycythemia Vera With Gleevec : Polycythemia Vera : 2010-05-07 : Drug: Gleevec 400 mg once daily for 12 months Other |
Recruiting |
: Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available. : Polycythemia Vera : 2014-11-05 : Drug: Ruxolitinib |
Active, not recruiting |
: Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL) : Polycythemia Vera : 2014-09-23 |
Completed |
: Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients : Polycythemia Vera : 2015-06-12 : Drug: Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen Subjects will continue to receive the do |
Completed |
: Effects of Imatinib Mesylate in Polycythemia Vera : Polycythemia Vera : 2007-01-31 : Drug: Imatinib Mesylate 400 mg/die for 6 months |
Active, not recruiting |
: AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. : Polycythemia Vera : 2014-08-14 :
|
Active, not recruiting |
: Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. : Polycythemia Vera : 2014-01-14 :
|
Terminated |
: Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera : Polycythemia Vera : 2009-12-22 : Drug: Erlotinib Erlotinib supplied as tablets; oral dose of erlotinib of 150 mg daily to be continued fo |